{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:55:22Z","timestamp":1786982122871,"version":"build-2736575974"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2020,11,23]],"date-time":"2020-11-23T00:00:00Z","timestamp":1606089600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,11,23]],"date-time":"2020-11-23T00:00:00Z","timestamp":1606089600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Diab Rep"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s11892-020-01359-z","type":"journal-article","created":{"date-parts":[[2020,11,23]],"date-time":"2020-11-23T12:05:25Z","timestamp":1606133125000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Sodium-Glucose Cotransporter Type 2 (SGLT-2) Inhibitors and Ketogenesis: the Good and the Bad"],"prefix":"10.1007","volume":"20","author":[{"given":"Preethika","family":"Ekanayake","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Hupfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4441-8508","authenticated-orcid":false,"given":"Sunder","family":"Mudaliar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,23]]},"reference":[{"issue":"6","key":"1359_CR1","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.jcjd.2016.10.004","volume":"40","author":"DC Lau","year":"2016","unstructured":"Lau DC. Are diabetes care providers too glucocentric? Can J Diabetes. 2016;40(6):479\u201381.","journal-title":"Can J Diabetes"},{"key":"1359_CR2","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","volume":"358","author":"The Action to Control Cardiovascular Risk in Diabetes Study Group","year":"2008","unstructured":"The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545\u201359.","journal-title":"N Engl J Med"},{"key":"1359_CR3","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117\u201328.","journal-title":"N Engl J Med"},{"issue":"7","key":"1359_CR4","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644\u201357.","journal-title":"N Engl J Med"},{"issue":"4","key":"1359_CR5","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347\u201357.","journal-title":"N Engl J Med"},{"issue":"21","key":"1359_CR6","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"\u2022\u2022 McMurray JJV, DAPA-HF Trial Committees and Investigators, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995\u20132008 First study to demonstrate that an SGLT2 inhibitor can reduce HF hospitalization\/CV mortality in patients with HFrEF irrespective of diabetes status.","journal-title":"N Engl J Med"},{"key":"1359_CR7","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380:2295\u2013306.","journal-title":"N Engl J Med"},{"key":"1359_CR8","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/S2213-8587(18)30141-4","volume":"6","author":"V Perkovic","year":"2018","unstructured":"Perkovic V, de Zeeuw D, Mahaffey KW, Fulcher G, Erondu N, Shaw W, et al. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS program randomized clinical trials. Lancet Diabetes Endocrinol. 2018;6:691\u2013704.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1359_CR9","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/NEJMoa1515920","volume":"375","author":"C Wanner","year":"2016","unstructured":"Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375:323\u201334.","journal-title":"N Engl J Med"},{"key":"1359_CR10","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/S2213-8587(19)30180-9","volume":"7","author":"O Mosenzon","year":"2019","unstructured":"Mosenzon O, Wiviott SD, Cahn A, Rozenberg A, Yanuv I, Goodrich EL, et al. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomized trial. Lancet Diabetes Endocrinol. 2019;7:606\u201317.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1359_CR11","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.2337\/dc16-0542","volume":"39","author":"S Mudaliar","year":"2016","unstructured":"Mudaliar S, Alloju S, Henry RR. Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME study? A unifying hypothesis. Diabetes Care. 2016;39:1115\u201322.","journal-title":"Diabetes Care"},{"key":"1359_CR12","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.2337\/db15-1356","volume":"65","author":"E Ferrannini","year":"2016","unstructured":"Ferrannini E, et al. Shift to fatty substrate utilization in response to sodium\u2013glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes. Diabetes. 2016;65:1190\u20135.","journal-title":"Diabetes"},{"key":"1359_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1146\/annurev.nutr.26.061505.111258","volume":"26","author":"GF Cahill","year":"2006","unstructured":"\u2022\u2022 Cahill GF. Fuel metabolism in starvation. Annu Rev Nutr. 2006;26:1\u201322 Comprehensive review of fuel metabolism in starvation.","journal-title":"Annu Rev Nutr"},{"key":"1359_CR14","first-page":"149","volume":"114","author":"GF Cahill Jr","year":"2003","unstructured":"Cahill GF Jr, Veech RL. Ketoacids? Good medicine? Trans Am Clin Climatol Assoc. 2003;114:149\u201363.","journal-title":"Trans Am Clin Climatol Assoc"},{"issue":"6","key":"1359_CR15","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1002\/(SICI)1520-7560(199911\/12)15:6<412::AID-DMRR72>3.0.CO;2-8","volume":"15","author":"L Laffel","year":"1999","unstructured":"Laffel L. Ketone bodies: a review of physiology, pathophysiology and application of monitoring to diabetes. Diabetes Metab Res Rev. 1999;15(6):412\u201326.","journal-title":"Diabetes Metab Res Rev"},{"issue":"3961","key":"1359_CR16","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1126\/science.170.3961.990","volume":"170","author":"P Felig","year":"1970","unstructured":"Felig P, Lynch V. Starvation in human pregnancy: hypoglycemia, hypoinsulinemia, and hyperketonemia. Science. 1970;170(3961):990\u20132.","journal-title":"Science."},{"key":"1359_CR17","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cmet.2017.04.011","volume":"26","author":"E Ferrannini","year":"2017","unstructured":"Ferrannini E. Sodium-glucose cotransporters and their inhibition: clinical physiology. Cell Metab. 2017;26:27\u201338.","journal-title":"Cell Metab"},{"issue":"5","key":"1359_CR18","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1111\/dom.13224","volume":"20","author":"D Polidori","year":"2018","unstructured":"Polidori D, Iijima H, Goda M, Maruyama N, Inagaki N, Crawford PA. Intra- and inter-subject variability for increases in serum ketone bodies in patients with type 2 diabetes treated with the sodium glucose co-transporter 2 inhibitor canagliflozin. Diabetes Obes Metab. 2018;20(5):1321\u20136.","journal-title":"Diabetes Obes Metab"},{"key":"1359_CR19","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1111\/dom.12848","volume":"19","author":"D Yabe","year":"2017","unstructured":"Yabe D, Iwasaki M, Kuwata H, Haraguchi T, Hamamoto Y, Kurose T, et al. Sodium-glucose co-transporter-2 inhibitor use and dietary carbohydrate intake in Japanese individuals with type 2 diabetes: a randomized, open-label, 3-arm parallel comparative, exploratory study. Diabetes Obes Metab. 2017;19:739\u201343.","journal-title":"Diabetes Obes Metab"},{"issue":"10166","key":"1359_CR20","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","volume":"393","author":"TA Zelniker","year":"2019","unstructured":"Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, et al. Sabatine MS.SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019;393(10166):31\u20139.","journal-title":"Lancet."},{"issue":"8","key":"1359_CR21","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1111\/dom.13740","volume":"21","author":"C Hupfeld","year":"2019","unstructured":"Hupfeld C, Mudaliar S. Navigating the \u201cMACE\u201d in cardiovascular outcomes trials and decoding the relevance of atherosclerotic cardiovascular disease benefits versus heart failure benefits. Diabetes Obes Metab. 2019;21(8):1780\u20139.","journal-title":"Diabetes Obes Metab"},{"key":"1359_CR22","unstructured":"FDA approves new treatment for a type of heart failure. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-treatment-type-heart-failure. Accessed June 27, 2020."},{"issue":"1","key":"1359_CR23","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3121\/cmr.2015.1282","volume":"14","author":"F Qiangwei","year":"2016","unstructured":"Qiangwei F, Colgan SP, Shelley CS. Hypoxia: the force that drives chronic kidney disease. Clin Med Res. 2016;14(1):15\u201339.","journal-title":"Clin Med Res"},{"issue":"9","key":"1359_CR24","doi-asserted-by":"publisher","first-page":"884","DOI":"10.5551\/jat.RV17009","volume":"24","author":"H Abe","year":"2017","unstructured":"Abe H, Semba H, Takeda N. The roles of hypoxia signaling in the pathogenesis of cardiovascular diseases. J Atheroscler Thromb. 2017;24(9):884\u201394.","journal-title":"J Atheroscler Thromb"},{"key":"1359_CR25","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1177\/193229680800200622","volume":"2","author":"YI Cho","year":"2008","unstructured":"Cho YI, Mooney MP, Cho DJ. Hemorheological disorders in diabetes mellitus. J Diabetes Sci Technol. 2008;2:1130\u20138.","journal-title":"J Diabetes Sci Technol"},{"key":"1359_CR26","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/1475-2840-11-110","volume":"11","author":"LJ Pu","year":"2012","unstructured":"Pu LJ, Shen Y, Lu L, Zhang RY, Zhang Q, Shen WF. Increased blood glycohemoglobin A1c levels lead to overestimation of arterial oxygen saturation by pulse oximetry in patients with type 2 diabetes. Cardiovasc Diabetol. 2012;11:110.","journal-title":"Cardiovasc Diabetol"},{"issue":"7","key":"1359_CR27","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/j.cjca.2017.03.009","volume":"33","author":"KA De Jong","year":"2017","unstructured":"De Jong KA, Lopaschuk GD. Complex energy metabolic changes in heart failure with preserved ejection fraction and heart failure with reduced ejection fraction. Can J Cardiol. 2017;33(7):860\u201371.","journal-title":"Can J Cardiol"},{"key":"1359_CR28","doi-asserted-by":"publisher","first-page":"68","DOI":"10.3389\/fcvm.2018.00068","volume":"5","author":"QG Karwi","year":"2018","unstructured":"Karwi QG, Uddin GM, Ho KL, Lopaschuk GD. Loss of metabolic flexibility in the failing heart. Front Cardiovasc Med. 2018;5:68.","journal-title":"Front Cardiovasc Med"},{"key":"1359_CR29","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/S1043-2760(02)00598-2","volume":"13","author":"DA Okar","year":"2002","unstructured":"Okar DA. Starvation amidst plenty: PDKs and diabetes mellitus. Trends Endocrinol Metab. 2002;13:142.","journal-title":"Trends Endocrinol Metab"},{"issue":"9","key":"1359_CR30","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1161\/ATVBAHA.111.241984","volume":"32","author":"ED Abel","year":"2012","unstructured":"Abel ED, O'Shea KM, Ramasamy R. Insulin resistance: metabolic mechanisms and consequences in the heart. Arterioscler Thromb Vasc Biol. 2012;32(9):2068\u201376.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"46","key":"1359_CR31","doi-asserted-by":"publisher","first-page":"3461","DOI":"10.1093\/eurheartj\/ehv442","volume":"37","author":"E Levelt","year":"2016","unstructured":"Levelt E, Rodgers CT, Clarke WT, Mahmod M, Ariga R, Francis JM, et al. Cardiac energetics, oxygenation, and perfusion during increased workload in patients with type 2 diabetes mellitus. Eur Heart J. 2016;37(46):3461\u20139.","journal-title":"Eur Heart J"},{"issue":"10","key":"1359_CR32","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1016\/j.bbalip.2016.03.014","volume":"1861","author":"F Pascual","year":"2016","unstructured":"Pascual F, Coleman RA. Fuel availability and fate in cardiac metabolism: a tale of two substrates. Biochim Biophys Acta. 2016;1861(10):1425\u201333.","journal-title":"Biochim Biophys Acta"},{"issue":"1","key":"1359_CR33","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s12933-020-01066-9","volume":"19","author":"S Lahnwong","year":"2020","unstructured":"Lahnwong S, Palee S, Apaijai N, Sriwichaiin S, Kerdphoo S, Jaiwongkam T, et al. Acute dapagliflozin administration exerts cardioprotective effects in rats with cardiac ischemia\/reperfusion injury. Cardiovasc Diabetol. 2020;19(1):91.","journal-title":"Cardiovasc Diabetol"},{"issue":"8","key":"1359_CR34","doi-asserted-by":"publisher","first-page":"165807","DOI":"10.1016\/j.bbadis.2020.165807","volume":"2020","author":"J Moellmann","year":"1866","unstructured":"Moellmann J, Klinkhammer BM, Droste P, et al. Empagliflozin improves left ventricular diastolic function of db\/db mice [published online ahead of print, 2020 Apr 28]. Biochim Biophys Acta Mol basis Dis. 1866;2020(8):165807.","journal-title":"Biochim Biophys Acta Mol basis Dis"},{"issue":"15","key":"1359_CR35","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1016\/j.jacc.2019.01.056","volume":"73","author":"CG Santos-Gallego","year":"2019","unstructured":"Santos-Gallego CG, Requena-Ibanez JA, San Antonio R, Ishikawa K, Watanabe S, Picatoste B, et al. Empagliflozin ameliorates adverse left ventricular remodeling in nondiabetic heart failure by enhancing myocardial energetics. J Am Coll Cardiol. 2019;73(15):1931\u201344.","journal-title":"J Am Coll Cardiol"},{"issue":"18","key":"1359_CR36","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1161\/CIRCULATIONAHA.118.036459","volume":"139","author":"R Nielsen","year":"2019","unstructured":"\u2022\u2022 Nielsen R, M\u00f8ller N, Gormsen LC, et al. Cardiovascular effects of treatment with the ketone body 3-hydroxybutyrate in chronic heart failure patients. Circulation. 2019;139(18):2129\u201341 First study in humans to show that BHOB infusion may potentially constitute a novel treatment principle in HFrEF patients.","journal-title":"Circulation"},{"issue":"11","key":"1359_CR37","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1016\/S0735-1097(20)32237-3","volume":"75","author":"J Oldgren","year":"2020","unstructured":"Oldgren J, Laurila S, Akerblom A, et al. Effects of 6 weeks of treatment with dapagliflozin, a sodium-glucose cotransporter 2 inhibitor, on myocardial function and metabolism in type 2 diabetes patients: a randomized placebo-controlled study. J Am Coll Cardiol. 2020;75(11):1610.","journal-title":"J Am Coll Cardiol"},{"key":"1359_CR38","unstructured":"EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03057951. Accessed 27 June 2020."},{"key":"1359_CR39","unstructured":"Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure. (DELIVER). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03619213. Accessed 27 June 2020."},{"issue":"2","key":"1359_CR40","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1111\/1440-1681.12034","volume":"40","author":"P Hansell","year":"2013","unstructured":"Hansell P, Welch WJ, Blantz RC, Palm F. Determinants of kidney oxygen consumption and their relationship to tissue oxygen tension in diabetes and hypertension. Clin Exp Pharmacol Physiol. 2013;40(2):123\u201337.","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"1359_CR41","first-page":"S74","volume":"65","author":"LG Fine","year":"1998","unstructured":"Fine LG, Orphanides C, Norman JT. Progressive renal disease: the chronic hypoxia hypothesis. Kidney Int Suppl. 1998;65:S74\u20138.","journal-title":"Kidney Int Suppl"},{"key":"1359_CR42","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1161\/HYPERTENSIONAHA.113.01425","volume":"62","author":"Friederich-Persson","year":"2013","unstructured":"Friederich-Persson, et al. Kidney hypoxia, attributable to increased oxygen consumption, induces nephropathy independently of hyperglycemia and oxidative stress. Hypertension. 2013;62:914\u20139.","journal-title":"Hypertension"},{"key":"1359_CR43","doi-asserted-by":"publisher","first-page":"629","DOI":"10.2337\/diab.43.5.629","volume":"43","author":"A K\u00f6rner","year":"1994","unstructured":"K\u00f6rner A, Ekl\u00f6f AC, Celsi G, Aperia A. Increased renal metabolism in diabetes. Mechanism and functional implications. Diabetes. 1994;43:629\u201333.","journal-title":"Diabetes"},{"issue":"6","key":"1359_CR44","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1007\/s12325-018-0708-y","volume":"35","author":"ME Muller","year":"2018","unstructured":"Muller ME, Pruijm M, Bonny O, Burnier M, Zanchi A. Effects of the SGLT-2 inhibitor empagliflozin on renal tissue oxygenation in non-diabetic subjects: a randomized, double-blind, placebo-controlled study protocol. Adv Ther. 2018;35(6):875\u201385.","journal-title":"Adv Ther"},{"key":"1359_CR45","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.cmet.2016.12.022","volume":"25","author":"P Puchalska","year":"2017","unstructured":"Puchalska P, Crawford PA. Multi-dimensional roles of ketone bodies in fuel metabolism, signaling, and therapeutics. Cell Metab. 2017;25:262\u201384.","journal-title":"Cell Metab"},{"key":"1359_CR46","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/nm.3893","volume":"21","author":"H Guo","year":"2015","unstructured":"Guo H, Callaway JB, Ting JP. Inflammasomes: mechanism of action, role in disease and therapeutics. Nat Med. 2015;21:677\u201387.","journal-title":"Nat Med"},{"key":"1359_CR47","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1038\/nrcardio.2009.57","volume":"6","author":"GE McKellar","year":"2009","unstructured":"McKellar GE, et al. Role for TNF in atherosclerosis? Lessons from autoimmune disease. Nat Rev Cardiol. 2009;6:410\u20137.","journal-title":"Nat Rev Cardiol"},{"issue":"3","key":"1359_CR48","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.celrep.2018.09.058","volume":"25","author":"S Chakraborty","year":"2018","unstructured":"Chakraborty S, Galla S, Cheng X, Yeo JY, Mell B, Singh V, et al. Salt-responsive metabolite, beta-hydroxybuterate, attenuates hypertension. Cell Rep. 2018;25(3):677\u201389.","journal-title":"Cell Rep"},{"key":"1359_CR49","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1038\/s41467-020-15983-6","volume":"11","author":"SR Kim","year":"2020","unstructured":"Kim SR, Lee SG, Kim SH, Kim JH, Choi E, Cho W, et al. SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease. Nat Commun. 2020;11:2127.","journal-title":"Nat Commun"},{"issue":"9","key":"1359_CR50","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1161\/CIRCRESAHA.110.223545","volume":"107","author":"F Giacco","year":"2010","unstructured":"Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res. 2010;107(9):1058\u201370.","journal-title":"Circ Res"},{"issue":"4","key":"1359_CR51","doi-asserted-by":"publisher","first-page":"a018713","DOI":"10.1101\/cshperspect.a018713","volume":"6","author":"E Seto","year":"2014","unstructured":"Seto E, Yoshida M. Erasers of histone acetylation: the histone deacetylase enzymes. Cold Spring Harb Perspect Biol. 2014;6(4):a018713.","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"5","key":"1359_CR52","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1080\/15592294.2015.1024406","volume":"10","author":"JY Ooi","year":"2015","unstructured":"Ooi JY, Tuano NK, Rafehi H, et al. HDAC inhibition attenuates cardiac hypertrophy by acetylation and deacetylation of target genes. Epigenetics. 2015;10(5):418\u201330.","journal-title":"Epigenetics."},{"key":"1359_CR53","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1161\/CIRCULATIONAHA.119.042375","volume":"140","author":"Verma","year":"2019","unstructured":"Verma, EMPA-HEART CardioLink-6 Investigators, et al. Effect of empagliflozin on left ventricular mass in patients with type 2 diabetes mellitus and coronary artery disease. Circulation. 2019;140:1693\u2013702.","journal-title":"Circulation"},{"issue":"5","key":"1359_CR54","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.echo.2020.02.005","volume":"33","author":"K Bami","year":"2020","unstructured":"Bami K, Gandhi S, Leong-Poi H, Yan AT, Ho E, Zahrani M, et al. Effects of empagliflozin on left ventricular remodeling in patients with type 2 diabetes and coronary artery disease: echocardiographic substudy of the EMPA-HEART CardioLink-6 randomized clinical trial. J Am Soc Echocardiogr. 2020;33(5):644\u20136.","journal-title":"J Am Soc Echocardiogr"},{"key":"1359_CR55","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1038\/ki.2014.111","volume":"86","author":"X Wang","year":"2014","unstructured":"Wang X, Liu J, Zhen J, Zhang C, Wan Q, Liu G, et al. Histone deacetylase 4 selectively contributes to podocyte injury in diabetic nephropathy. Kidney Int. 2014;86:712\u201325.","journal-title":"Kidney Int"},{"key":"1359_CR56","doi-asserted-by":"publisher","first-page":"2630","DOI":"10.3390\/ijms19092630","volume":"19","author":"MJ Hadden","year":"2018","unstructured":"Hadden MJ, Advani A. Histone deacetylase inhibitors and diabetic kidney disease. Int J Mol Sci. 2018;19:2630.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"1359_CR57","doi-asserted-by":"publisher","first-page":"6791","DOI":"10.1038\/s41598-018-25054-y","volume":"8","author":"H Umino","year":"2018","unstructured":"Umino H, Hasegawa K, Minakuchi H, Muraoka H, Kawaguchi T, Kanda T, et al. High basolateral glucose increases sodium-glucose cotransporter 2 and reduces sirtuin-1 in renal tubules through glucose transporter-2 detection. Sci Rep. 2018;8(1):6791.","journal-title":"Sci Rep"},{"issue":"3","key":"1359_CR58","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.mcna.2016.12.011","volume":"101","author":"M Fayfman","year":"2017","unstructured":"Fayfman M, Pasquel FJ, Umpierrez GE. Management of hyperglycemic crises: diabetic ketoacidosis and hyperglycemic hyperosmolar state. Med Clin North Am. 2017;101(3):587\u2013606.","journal-title":"Med Clin North Am"},{"key":"1359_CR59","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s11892-020-01307-x","volume":"20","author":"BM Bonora","year":"2020","unstructured":"Bonora BM, Avogaro A, Fadini GP. Euglycemic ketoacidosis. Curr Diab Rep. 2020;20:25.","journal-title":"Curr Diab Rep"},{"key":"1359_CR60","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.2337\/dc15-1380","volume":"38","author":"J Rosenstock","year":"2015","unstructured":"Rosenstock J, Ferranini E. Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors. Diabetes Care. 2015;38:1638\u201342.","journal-title":"Diabetes Care"},{"issue":"5","key":"1359_CR61","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1038\/nm.3828","volume":"21","author":"C Bonner","year":"2015","unstructured":"Bonner C, Kerr-Conte J, Gmyr V, Queniat G, Moerman E, Th\u00e9venet J, et al. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat Med. 2015;21(5):512\u20137.","journal-title":"Nat Med"},{"issue":"5","key":"1359_CR62","doi-asserted-by":"publisher","first-page":"864","DOI":"10.2337\/dbi19-0035","volume":"69","author":"DJ Hodson","year":"2020","unstructured":"Hodson DJ, Rorsman P. A variation on the theme: SGLT2 inhibition and glucagon secretion in human islets. Diabetes. 2020;69(5):864\u20136.","journal-title":"Diabetes."},{"key":"1359_CR63","unstructured":"First oral add-on treatment to insulin for treatment of certain patients with type 1 diabetes. https:\/\/www.ema.europa.eu\/en\/news\/first-oral-add-treatment-insulin-treatment-certain-patients-type-1-diabetes. Accessed June 27,2020."},{"key":"1359_CR64","doi-asserted-by":"publisher","unstructured":"Liu J, Li L, Li S, et al. Sodium-glucose co-transporter-2 inhibitors and the risk of diabetic ketoacidosis in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials [published online ahead of print, 2020 May 4]. Diabetes Obes Metab. 2020. https:\/\/doi.org\/10.1111\/dom.14075.","DOI":"10.1111\/dom.14075"},{"issue":"12","key":"1359_CR65","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1002\/pds.4887","volume":"28","author":"L Wang","year":"2019","unstructured":"Wang L, Voss EA, Weaver J, Hester L, Yuan Z, DeFalco F, et al. Diabetic ketoacidosis in patients with type 2 diabetes treated with SGLT2- inhibitors versus other antihyperglycemic agents: an observational study of four US administrative claims databases. Pharmacoepidemiol Drug Saf. 2019;28(12):1620\u20138.","journal-title":"Pharmacoepidemiol Drug Saf"}],"container-title":["Current Diabetes Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11892-020-01359-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11892-020-01359-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11892-020-01359-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,17]],"date-time":"2022-04-17T23:52:40Z","timestamp":1650239560000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11892-020-01359-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,23]]},"references-count":65,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1359"],"URL":"https:\/\/doi.org\/10.1007\/s11892-020-01359-z","relation":{},"ISSN":["1534-4827","1539-0829"],"issn-type":[{"value":"1534-4827","type":"print"},{"value":"1539-0829","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,23]]},"assertion":[{"value":"28 October 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"74"}}